TORnado Platform (Selective mTORC1 Inhibitor)
Improving Intrinsic Capacity in Older Adults / Age-related Metabolic Decline
Key Facts
About Cambrian Bio
Cambrian Bio is a New York-based, privately-held biotech founded in 2021 with an ambitious vision to modernize healthcare by developing preventative medicines that target the biology of aging. The company's strategy centers on its proprietary platforms, including the TORnado platform for selective mTORC1 inhibition and the Amplifier Therapeutics platform for AMPK activation and mitochondrial respiration, aimed at combating metabolic decline. It has achieved significant non-dilutive funding, notably a recent award of up to $30.8 million from ARPA-H's PROSPR program, validating its scientific approach. Operating as a decentralized 'company of companies,' Cambrian provides scientific and operational support to its pipeline programs, positioning itself at the forefront of the emerging longevity therapeutics field.
View full company profile